Status:
TERMINATED
A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)
Lead Sponsor:
Aristea Therapeutics, Inc.
Conditions:
Hidradenitis Suppurativa
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa
Eligibility Criteria
Inclusion
- Diagnosis of HS for at least 1 year prior to screening
- HS lesions must be present in at least 2 distinct anatomic areas
- A total AN count (sum of abscesses and inflammatory nodules) \> 6 across all anatomical sites at both the screening and baseline visits
- Willing to use contraception for the duration of the study
Exclusion
- Presence of other skin conditions which may interfere with study assessments
- Presence of active, chronic or latent bacterial, viral, fungal mycobacterial infection (including latent TB) or history of infection within 4 weeks of screening
- Body Mass Index (BMI) \>48kg/m2
- Breastfeeding or pregnant
Key Trial Info
Start Date :
July 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2023
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05348681
Start Date
July 18 2022
End Date
February 28 2023
Last Update
June 13 2023
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Cahaba Dermatology & Skin Center
Birmingham, Alabama, United States, 35244
2
Investigate MD, LLC
Scottsdale, Arizona, United States, 85255
3
USC IDS Pharmacy
Los Angeles, California, United States, 90033
4
Florida Academic Centers Research and Education, LLC
Coral Gables, Florida, United States, 33134